Association between glycosylated hemoglobin A1c and bone biochemical markers in type 2 diabetic postmenopausal women: a cross-sectional study

Table 3 Association between the level of HbA1c with bone biochemical markers in T2DM of postmenopausal women

	N-MID osteocalcin	PINP	β-CTX	PTH	25(OH)D₃
	β(95%CI)	β(95%CI)	β(95%CI)	β(95%CI)	β(95%CI)
HbA1c
Model1	−0.92 (−1.42, − 0.41)	−1.98 (−3.44, − 0.52)	− 0.01 (− 0.03, 0.00)	−1.29 (−2.91, 0.34)	0.05 (− 0.32, 0.42)
Model2	− 0.71 (− 1.19, − 0.22)	−1.79 (− 3.30, − 0.28)	−0.01 (− 0.03, 0.00)	−0.14 (− 1.49, 1.21)	−0.00 (− 0.39, 0.39)
Model3	− 0.71 (− 1.20, − 0.22)	− 1.80 (− 3.30, − 0.30)	−0.01 (− 0.03, 0.00)	−0.14 (− 1.50, 1.21)	−0.00 (− 0.39, 0.39)
Model4	− 0.71 (−1.20, − 0.22)	−1.85 (− 3.36, − 0.34)	− 0.01 (− 0.03, 0.01)	−0.13 (− 1.49, 1.24)	−0.02 (− 0.41, 0.37)
Model5	− 0.70 (− 1.20, − 0.20)	− 1.73 (− 3.27, − 0.20)	−0.01 (− 0.03, 0.01)	−0.10 (− 1.50, 1.29)	−0.10 (− 0.50, 0.30)

Values were based on linear regression models and reflect the difference and 95%CI for HbA1c, Model1 was non-adjusted, Model 2 was adjusted for age, BMI, menopause^’s years, diabetic duration, TC, TG, HDL-c, LDL-c, creatinine, UA and eGFR. Model 3 was adjusted for variables in Model 2 and history of fracture (Yes or No). model 4 was adjusted for variables in Mode3, microvascular complications (Yes or No) and macrovascular complication (Yes or No). model 5 was adjusted for variables in Mode4, the treatment of T2DM (insulin, anti-diabetic agents or insulin+ anti-diabetic agents) and the use of statin medication(Yes or No)

ISSN: 1472-6823